Table 3

Results of cross-reactivity by ATI levels for seven anti-adalimumab positive sera of patients with IBD unexposed to Remicade as measured towards two batches each of Remsima and Remicade

Serum numberAnti-Remicade batch DGM54013 ATI (μg/mL)Anti-Remicade batch 2RMKA83001ATI (μg/mL)Anti-Remsima batch 12B1C017 ATI (μg/mL)Anti-Remsima batch 12B1C019 ATI (μg/mL)
3931111.21.2
386310.91.31.2
38541.1111.1
3835111.21.2
38340.80.80.90.9
38111.61.72.32.3
36140.90.910.9
37541514.717.816.3
  • A positive control (serum 3754) is a patient previously exposed to Remicade before adalimumab, who became sensitised to Remicade and adalimumab.

  • ATI, antibodies to infliximab.